NUCB2 and nasopharyngeal carcinoma: By determining expression level of NUCB-2/nesfatin-1 in NPC cell lines, clinical tumor tissues and serum samples, our findings expand the possibility of NUCB-2/nesfatin-1 as a predictive biomarker for NPC development, and may contribute to develop novel therapeutics against primary NPC by targeting NUCB-2/nesfatin-1 involved signaling pathways.